Page 6 - Natco Pharma

Natco Pharma shares soar over 7% on nod for Tamiflu drugs

At NSE, it moved up by 6.89 per cent to touch its 52-week high of Rs 650

Natco Pharma hits 52-week high on USFDA nod for generic Tamiflu

The stock rallied 7% to Rs 650 also its 52-week high on the National Stock Exchange in early morning trade.

Natco Pharma gains on USFDA nod for generic Glycopyrrolate tablets

The stock was trading higher by 4% to Rs 552, extending its Wednesday's 6% rally on the BSE

Natco Pharma gains on tentative nod from USFDA for cancer drug

The stock up 9% to Rs 523 after the company said that its marketing partner, Mylan Inc., has received a US regulator tentative nod Sorafenib, the generic version of Nexavar.

Natco Pharma gains on sale of non-core business in US

The board approved the sale of Save Mart Pharmacy Stores located in USA which is non-core business

US regulator looms over Natco prospects

Company says no impact on product pipeline but Street awaits more clarity

Natco Pharma slips on USFDA observations

The stock slipped 11% to Rs 417 on the BSE in early morning trade.

USFDA observations on 2 units not to impact products: Natco

Natco Pharma Ltd has already sent response and compliance report for these observations